The FDA granted an emergency use authorization for Pemgarda, a monoclonal antibody for people who are immunocompromised to provide protection from COVID-19.
The FDA granted an emergency use authorization for Pemgarda, a monoclonal antibody for people who are immunocompromised to provide protection from COVID-19.
Our website services, content, and products are for informational purposes only. Healthline does not provide medical advice, diagnosis, or treatment and should not be used as a substitute for medical advice from a healthcare professional. Healthline encourages you to make any treatment decisions with your healthcare professional. Healthline is owned by RVO Health.
We've carried these sustainable handbags and purses everywhere from errands to dinners out — these are our top picks for materials, construction, and price. 👜
📝 A good question: It's April Fool's Day! (Don't worry, no tricks here.) What's the best goodnatured prank you've ever seen?
From Blake Cadwell, Co-Founder
"InsideTracker's telehealth and app-based products allowed me to get bloodwork for the first time in years, all remotely. The service isn't a replacement for primary care, but it can give you a great sense of where you are if you need a check-in on bloodwork and don't have a primary care physician." [Read my review]
A reader's old school hobby:
"Thank you for this, it helped connect some dots for me. When I was severely depressed a handful of years ago, and living with my parents, I started building guitars with my dad and it has become a high priority in my life now, even scaling back my office scheduled to spend more time in the woodshop. It helps me connect to something, have a sense of accomplishment, stretches my brain much more than my office job, and connects me to people."
Want to support The Good Trade? We're a women-led, small biz on a sincere mission to support you in your care of yourself, your community, and the planet. It means a lot to us to be in your inbox each morning. Here are a few ways you can support the newsletter.
